Suppr超能文献

丁酸梭菌宫入菌(CBM588)联合帕博利珠单抗治疗晚期尿路上皮癌的预后影响:一项回顾性队列研究

Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study.

作者信息

Arima Junya, Yoshino Hirofumi, Tatarano Shuichi, Mitsuke Akihiko, Osako Yoichi, Sakaguchi Takashi, Matsushita Ryosuke, Inoguchi Satoru, Yamada Yasutoshi, Enokida Hideki

机构信息

Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

出版信息

Cancer Rep (Hoboken). 2025 Aug;8(8):e70308. doi: 10.1002/cnr2.70308.

Abstract

BACKGROUND

Combining the probiotic product CBM588 with immune checkpoint inhibitors (ICIs) has shown improved prognosis in several cancers. Pembrolizumab alone as a second-line treatment for urothelial cancer (UC) extends prognosis by only 3 months.

AIMS

This is a retrospective study that examined the effects of CBM588 combined with pembrolizumab in advanced UC.

METHODS AND RESULTS

The study included 44 patients who had recurrence or progression after first-line chemotherapy with cisplatin or carboplatin. The study compared 33 patients treated with pembrolizumab alone and 11 patients treated with CBM588 plus pembrolizumab over a median observation period of 12 months. The combination of CBM588 and pembrolizumab significantly improved progression-free survival (PFS; p = 0.004) and overall survival (OS; p = 0.02). Multivariate analysis identified CBM588 as a significant prognostic factor for both PFS (hazard ratio: 0.074, p = 0.0008) and OS (hazard ratio: 0.105, p = 0.0056).

CONCLUSION

These results suggest the effectiveness of the CBM588 combination with ICI treatment in UC.

摘要

背景

将益生菌产品CBM588与免疫检查点抑制剂(ICI)联合使用已在多种癌症中显示出预后改善。帕博利珠单抗单药作为尿路上皮癌(UC)的二线治疗,仅将预后延长3个月。

目的

这是一项回顾性研究,旨在探讨CBM588联合帕博利珠单抗治疗晚期UC的效果。

方法与结果

该研究纳入了44例一线接受顺铂或卡铂化疗后复发或进展的患者。研究比较了33例仅接受帕博利珠单抗治疗的患者和11例接受CBM588加帕博利珠单抗治疗的患者,中位观察期为12个月。CBM588与帕博利珠单抗联合使用显著改善了无进展生存期(PFS;p = 0.004)和总生存期(OS;p = 0.02)。多变量分析确定CBM588是PFS(风险比:0.074,p = 0.0008)和OS(风险比:0.105,p = 0.0056)的显著预后因素。

结论

这些结果表明CBM588联合ICI治疗UC有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验